Analysts See Multiple Growth Levers For CVS Health In 2026

Group 1 - CVS Health Corp. reported sales of $105.69 billion, exceeding the consensus estimate of $103.59 billion [1] - Adjusted earnings were $1.09 per share, surpassing the analyst estimate of 99 cents, but decreased from $1.19 in the prior year [1] - The company reaffirmed its fiscal 2026 adjusted earnings guidance of $7.00-$7.20 per share, compared to the Street consensus of $7.17, indicating a strong position for 2026 [1] Group 2 - CVS updated its cash flow from operations guidance to at least $9.0 billion, down from at least $10.0 billion [2] - The company anticipates fiscal 2026 revenue of at least $400 billion, below the consensus of $409.77 billion, with adjusted operating income projected between $15.07 billion and $15.41 billion [2] Group 3 - Bank of America Securities views the reaffirmation of the 2026 guidance positively amid investor concerns regarding Medicare Advantage headwinds in 2027 and regulatory scrutiny in the pharmacy benefit manager sector [3] - In Health Care Benefits, group Medicare Advantage rate renewals are seen as opportunities to improve margins, supported by progress in Individual Medicare Advantage [4] - Analyst Allen Lutz noted that CVS has several strategies to counteract headwinds from the 2027 preliminary rate notice, including share repurchases and repricing of Group Medicare Advantage [4] Group 4 - In Health Services, Bank of America expects continued margin improvement in Oak Street due to clinic closures, fewer new openings, and growing patient panels, which support a path toward break-even [5] - Overall, Bank of America sees multiple levers in place to drive CVS's enterprise growth and maintains a positive outlook on the long-term strategy, reiterating a Buy rating with a price forecast of $95 [5] - CVS Health shares were up 0.87% at $76.36 at the time of publication [5]